Burzynski Research Institute, Inc. (BRI) Presents Promising Phase II Data on Malignant Glioma
HOUSTON & LAS VEGAS--(BUSINESS WIRE)--Nov 21, 2008 - Today at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology, BRI announced encouraging results from the ongoing Phase II clinical trials of two of its investigational drugs, Atengenal (A10) and Astugenal (AS2-1), defined as antineoplastons therapy (ANP). The meeting is currently taking place in Loews Lake, Las Vegas, Nevada.
Background – Phase II Study in Anaplastic Astrocytoma
In this Phase II clinical trial, ANP is administered daily on an outpatient basis, via an ambulatory infusion pump, to adult patients with newly-diagnosed anaplastic astrocytoma (AA), a common type of malignant glioma. The prognosis for patients with AA is usually poor with five-year's survival in less than 30% of patients, even after surgery, chemotherapy and radiation therapy.
The report being presented summarizes the treatment of a group of 20 evaluable patients, none of whom received radiation or chemotherapy prior to starting ANP. Six patients underwent surgery and had residual tumor; and 14 patients had biopsy only. ANP was well tolerated, with just two cases of serious reversible toxicities. Complete disappearance of tumors was achieved in 25% of patients, 40% of patients had stabilization of disease, and 35% of patients failed ANP treatment. Preliminary results indicate that satisfactory percentage of objective response to ANP was achieved. The Abstract was published in the October 2008 issue of Neuro-Oncology, the official journal of the Society of Neuro-Oncology.
Burzynski Research Institute, Inc. (OTCBB: BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and 19 Phase II clinical trials, some of which are coming now to a successful conclusion. Since antineoplastons effect approximately 100 genes instrumental in the growth of glioblastoma multiforme, the results of research will be presented in a number of neuro-oncology meetings and published as abstracts in Neuro-Oncology. Earlier this year the BRI team presented at the 13th International Symposium of Pediatric Neuro-Oncology in Chicago, Illinois (June 29-July 2, 2008), a successful preliminary report on the Phase II study of antineoplastons A10 and AS2-1 in children with optic pathway glioma. At the September 2008 annual meeting of the European Association for Neuro-Oncology in Barcelona, Spain, BRI presented two reports. In one of them, it was described how the ingredients of ANP down-regulate glycolysis pathways in glioblastoma cells. The second report described preliminary successful results of Phase II study of ANP in patients with recurrent anaplastic astrocytoma.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Burzynski Research Institute, Inc. cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for Antineoplastons A10 and AS2-1. BRI does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein.
Contact: Burzynski Research Institute, Inc.
Darlene Hodge, 713-335-5636; Darlene@burzynskiclinic.com
Carolyn Powers, 713-335-5664; Carolyn@burzynskiclinic.com
Amanda Cheslock, 212-446-1884; email@example.com
Posted: November 2008